Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

Laura Sánchez-Cenizo,1 Javier Aller,2 José Manuel Martínez-Sesmero,3 Nuria Mir,1 Carmen Peral,1 Darío Rubio-Rodríguez,4 Carlos Rubio-Terrés41Medical Department, Pfizer, S.L.U, Madrid, Spain; 2Endocronology Department, Hospital Univers...

Full description

Bibliographic Details
Main Authors:	Sánchez-Cenizo L, Aller J, Martínez-Sesmero JM, Mir N, Peral C, Rubio-Rodríguez D, Rubio-Terrés C
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-07-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	diabetes mellitus acromegaly burden of illness pegvisomant pasireotide.
Online Access:	https://www.dovepress.com/burden-of-diabetes-mellitus-in-patients-with-acromegaly-treated-with-s-peer-reviewed-article-CEOR

Similar Items

The position of combined medical treatment in acromegaly
by: Eva C. Coopmans, et al.
Published: (2020-01-01)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
by: A. Ciresi, et al.
Published: (2018-01-01)

New opportunities for secondary drug therapy of acromegaly
by: V. S. Pronin, et al.
Published: (2020-05-01)

Acromegaly: Beyond surgery
by: Gaya Thanabalasingham, et al.
Published: (2013-01-01)

The place of medical treatment of acromegaly in Serbia: Current status
by: Doknić Mirjana, et al.
Published: (2021-01-01)

Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)

Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)
by: Larisa K. Dzeranova, et al.
Published: (2019-12-01)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
by: Leandro Kasuki, et al.
Published: (2016-10-01)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01)

New cross-roads for second line medical therapy in acromegaly
by: Adina Ghemigian, et al.
Published: (2018-03-01)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
by: Lingyun Ma, et al.
Published: (2020-08-01)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
by: Greisa Vila, et al.
Published: (2020-11-01)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
by: Natalia Ximena Garcia Basavilbaso, et al.

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01)

Brazilian multicenter study on pegvisomant treatment in acromegaly
by: Cesar L. Boguszewski, et al.

GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study
by: Sabrina Chiloiro, et al.
Published: (2024-08-01)

Management of persistent acromegaly following primary therapy: The current landscape in the UK
by: Nikolaos Kyriakakis, et al.
Published: (2020-07-01)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
by: Soraya Puglisi, et al.
Published: (2020-02-01)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
by: Nelma Veronica Marques, et al.
Published: (2023-09-01)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
by: Rosa Maria Paragliola, et al.
Published: (2018-03-01)

Pegvisomant therapy in acromegalic patient resistant to other treatment: case report
by: Emilia Nowicka, et al.
Published: (2022-06-01)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
by: Przemysław Witek, et al.
Published: (2021-03-01)

Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review
by: De Fano M, et al.
Published: (2024-07-01)

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement
by: Sylvère Störmann, et al.
Published: (2024-02-01)

Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly
by: Chaitanya Gandhi, et al.
Published: (2025-01-01)

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly
by: Jan-Shun Chang, et al.
Published: (2016-06-01)

Guidelines on diagnostics and treatment of acromegaly (draft)
by: E. G. Przhiyalkovskaya, et al.
Published: (2024-08-01)

A Rare Case of McCune-Albright Syndrome in Association with Acromegaly: Treatment Options and a Review of the Literature
by: Hande Peynirci, et al.
Published: (2022-12-01)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
by: Mônica Gadelha, et al.
Published: (2020-02-01)

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study
by: Ulla Feldt-Rasmussen, et al.
Published: (2024-03-01)

Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01)

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences
by: Sabrina Chiloiro, et al.
Published: (2024-05-01)

Carbohydrate metabolism in patients with acromegaly and Itsenko—Cushing disease
by: L V Matchekhina, et al.
Published: (2015-10-01)

Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
by: Przemysław Witek, et al.
Published: (2024-12-01)

Cost-Utility of Acromegaly Pharmacological Treatments in a French Context
by: Thierry Brue, et al.
Published: (2021-10-01)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
by: Alessandro Mondin, et al.
Published: (2022-07-01)

Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review
by: Maria Kamusheva, et al.
Published: (2019-01-01)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
by: Adrian F Daly, et al.
Published: (2019-04-01)

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study
by: Vittoria Favero, et al.
Published: (2024-02-01)